---

Case Analysis: Mr. Aribabu, 71M - Prostate Carcinoma with Nodal Metastasis

---

Patient Overview

---

Examination Findings and Abnormalities

General Examination

1. Lymphatic obstruction from nodal metastasis impairs lymphatic drainage from lower limbs.
2. Hyponatremia (Na 128 mEq/L) - low oncotic state.
3. Renal impairment (Creatinine 3.3 mg/dL, eGFR ~17.8 mL/min) - fluid retention due to reduced renal excretory capacity.

Vitals

• Fever (39.6°C): Suggestive of infection/sepsis. Note: Cancer itself can cause fever (tumor fever), but in this case the WBC and neutrophilia (see CBC) point toward active bacterial infection. This justifies the IV antibiotic plan.
• BP 100/70: Low-normal; in context of infection and edema, this suggests early sepsis physiology or medication effect.
• SpO₂ 94%: Mild hypoxia; warrants monitoring. Normal is ≥95-96%.

Systemic Examination

• CVS: S1, S2 heard - normal heart sounds.
• RS: Clear - no respiratory compromise.
• Abdomen: Soft, non-tender.
• CNS: No focal neurological deficit.

---

Laboratory Investigations and Abnormalities

Complete Blood Count (CBC)

• Anemia of chronic disease (cancer-related, most likely)
• Bone marrow infiltration by prostate cancer metastases can suppress erythropoiesis
• Renal failure (eGFR 17.8) causes reduced erythropoietin production, leading to anemia

Differential Count

1. Active bacterial infection / sepsis - drives neutrophil production and relative lymphocyte suppression
2. Stress response (cortisol-mediated demargination of neutrophils)
3. The high fever + neutrophilia strongly supports active infection requiring IV antibiotics

Renal Function Tests

• Obstructive uropathy - prostate carcinoma causing urinary outflow obstruction, leading to hydronephrosis and renal damage (this patient is admitted to Nephrology for this exact reason)
• Pre-renal component from low BP (100/70) and infection
• Chronic kidney disease progression

Serum Electrolytes

• SIADH (Syndrome of Inappropriate ADH secretion) - a paraneoplastic phenomenon in advanced cancer
• Dilutional hyponatremia from renal failure/fluid retention
• This explains the prescription of sodium chloride (Tab Addna) at discharge

Urine Analysis

---

Provisional Diagnosis

• Scrotal pain (possible metastatic spread)
• Lymphadenopathy on examination
• Bilateral pedal edema (lymphatic + renal obstruction)
• Renal failure (obstructive uropathy from prostate enlargement)
• Past history of cancer

---

Treatment Chart - Drug-by-Drug Explanation

1. Inj. Cefglobes Forte - Cefoperazone + Sulbactam 1.5 g IV BD (27/6)

• Class: Extended-spectrum beta-lactam + beta-lactamase inhibitor combination
• Mechanism: Cefoperazone (3rd gen cephalosporin) inhibits bacterial cell wall synthesis by binding to Penicillin-Binding Proteins. Sulbactam inhibits beta-lactamase enzymes produced by resistant bacteria, protecting cefoperazone from degradation.
• Indication here: Broad-spectrum coverage for suspected gram-negative infection/sepsis; justified by fever (39.6°C), leukocytosis, neutrophilia, and mild pyuria. Switched to Meropenem on 29/6 suggesting escalation for treatment failure or worsening.
• Dosing: 1.5 g IV every 12 hours (1-0-1).

2. Inj. Pan - Pantoprazole 40 mg IV BD (27/6)

• Class: Proton Pump Inhibitor (PPI)
• Mechanism: Irreversibly blocks H⁺/K⁺ ATPase (proton pump) in gastric parietal cells, suppressing acid secretion.
• Indication here: Gastroprotection - given prophylactically to prevent stress ulcers in a seriously ill hospitalized patient, and to protect against GI irritation from other medications.

3. Inj. Emeset - Ondansetron 4 mg IV TDS (27/6)

• Class: 5-HT₃ receptor antagonist (antiemetic)
• Mechanism: Blocks serotonin (5-HT₃) receptors in the chemoreceptor trigger zone and gut, preventing nausea and vomiting.
• Indication here: Control of nausea/vomiting related to the underlying illness, pain medications, or other drugs.
• Drug interaction noted: Ondansetron + Tramadol - ondansetron may decrease the analgesic effect of tramadol (by blocking serotonin-mediated analgesia component) while paradoxically increasing serotonergic toxicity risk.

4. Tab Nacsave - Acetylcysteine + Taurine 150/100 mg PO BD (27/6)

• Class: Antioxidant / hepatoprotective / nephroprotective combination
• Mechanism: N-Acetylcysteine (NAC) replenishes glutathione, a key antioxidant, protecting against oxidative stress in renal tubular cells. Taurine is a conditionally essential amino acid with cytoprotective and antioxidant properties.
• Indication here: Nephroprotection in the context of Stage 4 CKD (Creatinine 3.3 mg/dL, eGFR 17.8). NAC is well-recognized in CKD/contrast nephropathy prevention.

5. Tab Sodacel - Sodium Bicarbonate 500 mg PO TDS (28/6)

• Class: Alkalinizing agent
• Mechanism: Provides bicarbonate to correct metabolic acidosis by buffering excess H⁺ ions.
• Indication here: Correction of metabolic acidosis (low bicarbonate 21.7 mEq/L) due to renal failure. Also helps reduce uric acid crystallization in tubules in CKD.

6. Inj. Tramadol - Tramadol HCl 50 mg IV Stat (PRN)

• Class: Centrally acting synthetic opioid analgesic (weak µ-opioid agonist + SNRI)
• Mechanism: Dual action - (1) weak agonism at µ-opioid receptors providing analgesia, and (2) inhibits reuptake of serotonin and norepinephrine, enhancing descending pain inhibition pathways. (Katzung's Basic and Clinical Pharmacology, 16th Ed.)
• Indication here: Pain management for scrotal pain - given as a "stat" dose for immediate pain relief.
• Drug interactions:
  • With ondansetron - decreased therapeutic effect + serotonin syndrome risk
  • With abiraterone - abiraterone inhibits CYP2D6, reducing tramadol metabolism, thereby increasing tramadol plasma levels and toxicity risk
  • With alcohol - additive CNS depression

7. Sachet Lamino Nephro - Amino acid supplement PO BD (29/6)

• Class: Nephrology nutritional supplement (keto/amino acid formula)
• Mechanism: Essential and keto amino acids supplement protein nutrition in CKD patients without adding to nitrogen/urea load. These supplements help prevent protein-energy malnutrition in dialysis/pre-dialysis patients.
• Indication here: Nutritional support for Stage 4 CKD (eGFR 17.8), anemia of chronic disease, and underlying malignancy.

8. Inj. Meropenem - Meropenem 1 g IV OD (29/6)

• Class: Carbapenem (ultra-broad-spectrum beta-lactam antibiotic)
• Mechanism: Inhibits bacterial cell wall synthesis by binding to multiple PBPs; more resistant to beta-lactamases than earlier agents. Covers gram-positives, gram-negatives (including Pseudomonas), and anaerobes.
• Indication here: Escalation from Cefoperazone-Sulbactam, likely due to clinical deterioration or suspicion of resistant organisms. The once-daily dosing (1-0-0) noted here may reflect dose adjustment for renal impairment (normal dosing is 1 g TDS).

9. Tab Addna - Sodium Chloride 1 g PO BD (30/6)

• Indication here: Oral sodium replacement to correct hyponatremia (Na 128 mEq/L). Given the very low urine sodium (6 mEq/L), the kidneys are retaining sodium avidly, but oral supplementation helps restore total body sodium.

10. Tab Abiraterone Acetate - 500 mg PO OD (morning, fasting) (30/6)

• Class: CYP17A1 inhibitor / Androgen biosynthesis inhibitor - KEY anti-cancer drug in this case
• Mechanism: Abiraterone is a potent, selective, irreversible inhibitor of CYP17A1 (17α-hydroxylase/C17,20-lyase), a cytochrome P450 enzyme expressed in the adrenal glands, testes, and prostate tumor tissue. This enzyme is essential for androgen biosynthesis. By blocking CYP17A1, abiraterone dramatically reduces circulating androgens (testosterone, DHEA) - including those produced extragonadally - thereby depriving androgen-dependent prostate cancer cells of the growth signal they depend on.
• Standard dose: 1000 mg/day (often given as 2 × 500 mg), taken on an empty stomach (food increases absorption by up to 17-fold with a high-fat meal, dramatically increasing toxicity).
• Indication here: Metastatic castration-resistant prostate cancer (mCRPC) with nodal metastasis.
• Dosing regimen: 2-0-0 (two tablets, once in morning, fasting) = 1000 mg OD - correct standard dosing.

---

Discharge Medications Summary

---

Pharmacist Interventions (Drug Interactions)

Drug-Drug Interactions

Drug-Food Interactions

---

Summary of Abnormalities and Their Clinical Connections